The PROMISE Study: Duavee in Women With DCIS

PHASE2CompletedINTERVENTIONAL
Enrollment

142

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

June 19, 2024

Study Completion Date

June 19, 2024

Conditions
Ductal Breast Carcinoma In SituPostmenopausal
Interventions
DRUG

Conjugated Estrogens/Bazedoxifene

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

OTHER

Placebo

Given PO

PROCEDURE

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (10)

15213

University of Pittsburg/ Magee-Womens Hospital, Pittsburgh

19107

Thomas Jefferson University, Philadelphia

21287

John's Hopkins University, Baltimore

60045

Northwestern University, Lake Forest

60134

Northwestern Medicine - Delnor/Warrenville Cancer Centers/Central DuPage Hospital, Geneva

60611

Northwestern University, Chicago

63110

Washington University in St. Louis/ Siteman Cancer Center, St Louis

80045

University of Colorado at Denver/ Department of Surgery, Aurora

84112

Huntsman Cancer Institute, Salt Lake City

02115

Dana Farber/Partners Cancer Care Inc, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Pfizer

INDUSTRY

collaborator

University of Chicago - Department for Cancer Research

UNKNOWN

collaborator

University of California, San Francisco

OTHER

lead

Northwestern University

OTHER

NCT02694809 - The PROMISE Study: Duavee in Women With DCIS | Biotech Hunter | Biotech Hunter